133 related articles for article (PubMed ID: 20705770)
1. Independently acquired biallelic JAK2 mutations are present in a minority of patients with essential thrombocythemia.
Beer PA; Ortmann CA; Campbell PJ; Green AR
Blood; 2010 Aug; 116(6):1013-4. PubMed ID: 20705770
[No Abstract] [Full Text] [Related]
2. JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.
Wang J; Zhang B; Chen B; Zhou RF; Zhang QG; Li J; Yang YG; Zhou M; Shao XY; Xu Y; Xu XH; Ouyang J; Xu J; Ye Q
Hematology; 2017 Apr; 22(3):145-148. PubMed ID: 27875935
[TBL] [Abstract][Full Text] [Related]
3. Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycthemia vera and essential thrombocythemia.
Trifa AP; Bănescu C; Voina CM; Popa Ș; Török-Vistai T; Bojan AS; Dima D; Zdrenghea M; Fetica B; Vișan S; Tomuleasa C; Pârvu A; Urian L; Pop B; Popov VM; Andreescu M; Popp RA
Blood Cells Mol Dis; 2018 Nov; 73():45-46. PubMed ID: 30249383
[No Abstract] [Full Text] [Related]
4. Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment.
Henry L; Carillo S; Jourdan E; Arnaud A; Brun S; Lavabre-Bertrand T
Am J Hematol; 2007 Jun; 82(6):500-1. PubMed ID: 17301972
[No Abstract] [Full Text] [Related]
5. Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients.
Muendlein A; Gasser K; Kinz E; Stark N; Leiherer A; Rein P; Saely CH; Grallert H; Peters A; Drexel H; Lang AH
Am J Hematol; 2014 Mar; 89(3):295-301. PubMed ID: 24265174
[TBL] [Abstract][Full Text] [Related]
6. The mutant JAK2 allele burden in children with essential thrombocythemia.
Teofili L; Cenci T; Martini M; Capodimonti S; Torti L; Giona F; Amendola A; Randi ML; Putti MC; Scapin M; Leone G; Larocca LM
Br J Haematol; 2009 May; 145(3):430-2. PubMed ID: 19208099
[No Abstract] [Full Text] [Related]
7. Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden.
Zalcberg IR; Ayres-Silva J; de Azevedo AM; Solza C; Daumas A; Bonamino M
Haematologica; 2011 Mar; 96(3):e18-20. PubMed ID: 21357711
[No Abstract] [Full Text] [Related]
8. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.
Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK
Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189
[TBL] [Abstract][Full Text] [Related]
10. JAK2, MPL, and CALR mutations in children with essential thrombocythemia.
Sekiya Y; Okuno Y; Muramatsu H; Ismael O; Kawashima N; Narita A; Wang X; Xu Y; Hama A; Fujisaki H; Imamura T; Hasegawa D; Kosaka Y; Sunami S; Ohtsuka Y; Ohga S; Takahashi Y; Kojima S; Shimada A
Int J Hematol; 2016 Aug; 104(2):266-7. PubMed ID: 27209416
[No Abstract] [Full Text] [Related]
11. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Rumi E; Pietra D; Ferretti V; Klampfl T; Harutyunyan AS; Milosevic JD; Them NC; Berg T; Elena C; Casetti IC; Milanesi C; Sant'antonio E; Bellini M; Fugazza E; Renna MC; Boveri E; Astori C; Pascutto C; Kralovics R; Cazzola M;
Blood; 2014 Mar; 123(10):1544-51. PubMed ID: 24366362
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis.
Cetin G; Ozkan T; Turgut S; Ali Cikrikcioglu M; Cem Ar M; Ayer M; Unlu A; Celik SR; Sekin Y; Karatoprak C
Mol Biol Rep; 2014 Oct; 41(10):6737-42. PubMed ID: 25012914
[TBL] [Abstract][Full Text] [Related]
13. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
14. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm.
Lambert JR; Everington T; Linch DC; Gale RE
Blood; 2009 Oct; 114(14):3018-23. PubMed ID: 19541820
[TBL] [Abstract][Full Text] [Related]
15. Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.
Park SH; Kim SY; Lee SM; Yi J; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS
Ann Lab Med; 2015 Mar; 35(2):233-7. PubMed ID: 25729726
[TBL] [Abstract][Full Text] [Related]
16. Identification of MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction.
Daly S; Conneally E; Langabeer SE
Acta Haematol; 2009; 121(4):221-2. PubMed ID: 19521067
[No Abstract] [Full Text] [Related]
17. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
18. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.
Trifa AP; Popp RA; Cucuianu A; Bănescu C; Tevet M; Martin B; Murat M; Vesa SC; Dima D; Cândea M; Militaru MS; Pop IV
Br J Haematol; 2015 Jan; 168(1):151-3. PubMed ID: 25103987
[No Abstract] [Full Text] [Related]
19. Essential thrombocythemia: scientific advances and current practice.
Tefferi A
Curr Opin Hematol; 2006 Mar; 13(2):93-8. PubMed ID: 16456375
[TBL] [Abstract][Full Text] [Related]
20. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.
Barbui T; Vannucchi AM; Buxhofer-Ausch V; De Stefano V; Betti S; Rambaldi A; Rumi E; Ruggeri M; Rodeghiero F; Randi ML; Bertozzi I; Gisslinger H; Finazzi G; Carobbio A; Thiele J; Passamonti F; Falcone C; Tefferi A
Blood Cancer J; 2015 Nov; 5(11):e369. PubMed ID: 26617062
[No Abstract] [Full Text] [Related]
[Next] [New Search]
